Guselkumab treatment of PsA improved Hgb levels and ⬇️ incidence of anemia ⭐️Anemia resolution associated with improved clinical status #ACR21 #ACRBest Abs#1331 @RheumNow https://t.co/nbG7DpMDaR https://t.co/rxWsVfNqed

• Guselkumab (TREMFYA®) Improves Anemia in Patients with Active Psoriatic Arthrit…

Knowledge Bowl at #ACR21 ⭐️This HLA allele confers a risk for a severe psoriasis phenotype, typically guttate type. ➡️HLA Cw6 @RheumNow

Abst1344 #ACR21 @RheumNow observational study of pts w/PsA treated w/b&tsDMARD:pts who achieve MDA (22.8% of pts at 6 mo) more likely to maintain the initiated bDMARD or tsDMARD Rx & less likely to switch from the initiated bDMARD/tsDMARD https://t.co/egFDHV3eQs

AQUILA study, SEC improved disease activity, depression of PsA patients in both men and women. Women showed overall higher burden of disease. SEC effective up to 52 weeks with high treatment retention rates irrespective of gender @RheumNow #ACR21 Abst#1334 https://t.co/9cPGq5M648 https://t.co/iTrkRWoot0

• How Does Gender Affect Secukinumab Treatment Outcomes and Retention Rates in Pa…

SEC demonstrated significantly longer time to flare vs PBO w/ sustained improvement of ERA and JPsA signs and symptoms up to Wk 104. No new safety signals. Plenary Abs 1424 #ACR21 #RheumNow @RheumNow https://t.co/VF2HmJ3Ha9 https://t.co/ApYFusADHX

• Secukinumab Treatment in Children and Adolescents with Enthesitis-related Arthr…

Post-hoc analysis of Deucravacitinib (TYK2i) for tx of PsA showed similar efficacy in pts with and without background csDMARD use. ⭐️>60% w/ background csDMARD use, majority of which was MTX ⭐️no difference in AE #ACR21 Abs#1352 @RheumNow https://t.co/nIJT7rNkJP https://t.co/bq0x1Ywguo

• Deucravacitinib Efficacy in Psoriatic Arthritis (PsA) by Baseline DMARD Use: Ex…

Younger age, male gender, geographic region, lower weight and BMI, dactylitis+ or enthesitis+, lower scores Pt-Pain, PtGA, TJC and HAQ-DI were baseline predictors for achieving MDA and DAPSA LDA at Week 56 in UPA treated patients @RheumNow #ACR21 Abst#1348 https://t.co/FSXarBoBM1 https://t.co/UMCjr6eCRm

• Predictors for Achievement of Low Disease Activity at Week 56 in Patients with …

Physical exercise did not increase BME disease in SIJ and spine in PsA. The risk of increased BME after 11 weeks of HIIT was not higher compared to controls in a cohort of PsA patients with low to moderate disease activity @RheumNow #ACR21 Abst#1362 https://t.co/DHj4D5Ojb1 https://t.co/J4KV5zdpey

• No Change in Bone Marrow Edema of the Sacroiliac Joints and Spine After High In…

Abst1424 #ACR2021 @RheumNow study of SEC in children w/ERA or JPsA : 72% reduced flare risk. Improved JADAS-27 score in both the ERA and JPsA categories. ⬇️ disease activity, enthesitis count & joints with active arthritis. adverse events & serious AEs in the SEC & PBO comparable https://t.co/J4MdxeYxWZ

PsO pts not on biologics had a ⬆️ risk of PsA compared to those on biologics ⭐️HR 1.39 ⭐️retrospective cohort study w/ >1300 cases Abs#1355 #ACR21 #ACRBest @RheumNow https://t.co/tL37we3lwc https://t.co/SAexvn9HMb

• Psoriatic Arthritis Incidence Among Patients Receiving Biologic Medications for…

In PsA patients with low baseline CRP treated with IXE or ADA, a favorable reduction in pain was observed for IXE-treated patients, irrespective of controlled or non-controlled inflammation, as measured by CRP or SJC improvement @RheumNow #ACR21 Abst#1341 https://t.co/Nl78oASmf5 https://t.co/2qSXQr2sQS

• Ixekizumab Shows a Pattern of Pain Improvement in Patients with and Without Mea…